Trial Profile

Treating severe paediatric asthma; a randomised controlled trial of mepolizumab and omalizumab (TREAT trial)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 31 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mepolizumab (Primary) ; Omalizumab
Indications Asthma
Focus Therapeutic Use
Acronyms TREAT

Most Recent Events

26 May 2023 Planned End Date changed from 31 Jul 2024 to 31 Jul 2026.
22 May 2023 Status changed from active, no longer recruiting to recruiting.
22 May 2023 Recruitment completion is expected on 31 Jan 2025, according to ISRCTN: Current Controlled Trials.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com